Biologics & Advanced Modalities CMC

Complex modalities need a CMC architecture that grows with the science.

XGene integrates process development, analytical strategy, control strategy, comparability, manufacturing readiness, validation and regulatory documentation so advanced programs can mature without disconnecting development science from the submission package.

When this service is the right fit

• Process understanding is advancing faster than the formal control strategy.
• Analytical methods and CQAs are evolving while comparability or specification decisions are already being made.
• Clinical-stage processes must scale or transfer without losing the rationale behind critical controls.
• Manufacturing deviations, raw-material variability or process changes raise comparability and filing questions.
• PPQ/commercial readiness requires coordination across development, manufacturing, quality and regulatory teams.
• Complex modality knowledge is fragmented across internal SMEs and external partners.

What XGene does

• Define modality-specific CQAs, process risks, analytical evidence and lifecycle decisions.
• Connect process-development history to control strategy and regulatory narrative.
• Assess comparability, transfer, validation/PPQ and manufacturing-readiness evidence.
• Review external-manufacturing dependencies and technical governance.
• Build CMC authoring/response architecture for IND/BLA/MAA and lifecycle submissions as applicable.
• Stress-test the program for scale, variability, process changes and reviewer-facing traceability.

What the engagement produces

• Advanced-modality CMC architecture map
• CQA/control-strategy and analytical gap assessment
• Comparability / change-risk framework
• Tech-transfer / PPQ readiness assessment
• CMC submission evidence map
• Priority development and regulatory closure roadmap

Productized starting point — Advanced Modality CMC Architecture Review

The Advanced Modality CMC Architecture Review is the recommended first engagement when the organization needs an independent, evidence-based view before committing to a larger remediation, authoring, transformation or execution program. It is designed to identify the decision-critical gaps, clarify scope and produce a prioritized path forward without forcing the client into an oversized engagement at the outset.

How XGene works

1. Define the modality, development phase and regulatory decision.

2. Map process, analytical, product and manufacturing evidence.

3. Diagnose gaps where scale, variability or partner interfaces threaten control.

4. Build the development-to-submission execution architecture.

5. Stress-test lifecycle changes, transfer, comparability and reviewer traceability.

Senior practitioners aligned to this work

• a senior XGene biologics CMC / MS&T practitioner
• Khaled Aamer, PhD

Experience brought to XGene

The following examples demonstrate relevant practitioner experience. They are not presented as XGene-delivered client outcomes unless explicitly stated otherwise.

• Prior-role PPQ/commercial approval support for three molecules at three sites, transfer of four late-stage/commercial molecules, biologics process development/validation and IND/BLA/sBLA/MAA authorship (a senior XGene biologics CMC / MS&T practitioner).
• CMC strategy and development experience spans biologics, gene therapy, ceDNA, nanoparticles, polymers and global CMO oversight (Khaled Aamer).

Engagement boundary

XGene does not force advanced modalities into a small-molecule template. The architecture is built around the product, process and evidence actually controlling quality.